Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1073-1076

  Bajaksouzian, Saralee ^a   Visalli, Melissa A ^b   Jacobs, Michael R ^a   Appelbaum, Peter C ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ARTICLE; DRUG MIXTURE; DRUG POTENTIATION; DRUG SENSITIVITY; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0030971512     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1073     Document Type: Article

References (30)

1. Appelbaum, P. C., S. K. Spangler, and L. Sollenberger. 1986. Susceptibility of nonfermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin, and cefpirome. J. Antimicrob. Chemother. 18:675-679.
2. Appelbaum, P. C., S. K. Spangler, and T. Tamarree. 1988. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin. Chemotherapy 34:40-45.
3. Appelbaum, P. C., J. Tamim, G. A. Pankuch, and R. C. Aber. 1983. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and aztreonam. Chemotherapy 29:337-344.
4. Bajaksouzian, S., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Antipneumococcal activities of cefpirome and cefolaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob. Agents Chemother. 40:1973-1976.
5. Barry, A. L., and P. C. Fuchs. 1991. In vitro activities ot sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob. Agents Chemother. 35:955-960.
6. Bergogone-Berezin, E., and M. L. Joly-Guillou. 1986. Comparative activity of imipenem, ccftazidime and cefotaxime against Acinetobacter calcoaceticus. J. Antimicrob. Chemother. 18(Suppl. E):35-39.
7. Braveny, I. 1994. In vitro activity of imipenem - a review. Eur. J. Clin. Microbiol. 3:456-462.
8. Cantón, E., J. Pemán, M. T. Jimenez, M. S. Ramón, and M. Gobernado. 1992. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob. Agents Chemother. 36:558-565.
9. Cappelletty, D. M., and M. J. Rybak. 1996. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:677-683.
10. Chin, N.-X., J.-W. Gu, K.-W. Yu, Y.-X. Zhang, and H. C. Neu. 1991. In vitro activity of sparfloxacin. Antimicrob. Agents Chemother. 35:567-571.
11. Decre, D., C. Benoit, M. L. Joly-Guillou, E. Bergogne-Berezin, and A. Bryskier. 1995 In vitro activity and bactericidal activity of levofloxacin (levx) alone or in combination with amikacin against Acinetobacter spp. in comparison with ofloxacin (ofl) and ciprofloxacin (cpl), abstr. E-100, p. 103. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Dholakia, N., K. V. I. Rolston, D. H. Ho, B. LeBlanc, and G. P. Bodey. 1994. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob. Agents Chemother. 38:848-852.
13. Eliopoulos, G. M., and R. C. Moellering, Jr. 1991. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore, Md.
14. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. F. Barrett, A. J. Tobia, and M. E. Rosenthale. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
15. Hoban, D. J., R. N. Jones, N. Yamane, R. Frei, A. Trilla, and A. C. Pignatari. 1993. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn. Microbiol. Infect. Dis. 17:299-305.
16. Husson, M. O., D. Izard, L. Bouillet, and H. Leclerc. 1985. Comparative in-vitro activity of ciprofloxacin against non-fermenters. J. Antimicrob. Chemother. 15:457-462.
17. Joly-Guillou, M. L., and E. Bergogne-Bérézin. 1992. In vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp. J. Antimicrob. Chemother. 29:466-468.
18. Kuah, B. G., G. Kumarasinghe, J. Doran, and H. R. Chang. 1994. Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore. Antimicrob. Agents Chemother. 38:2502-2503.
19. National Committee for Clinical Laboratory Standards. 1996. Publication no. M7-A4. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. Neu, H. C., and N.-X. Chin. 1989. In vitro activity of S-ofloxacin. Antimicrob. Agents Chemother. 33:1105-1107.
21. Pfaller, M. A., A. L. Barry, and P. C. Fuchs. 1993. Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. Antimicrob. Agents Chemother. 31:1924-1926.
22. Rolston, K. V. I., and G. P. Bodey. 1986. In vitro susceptibility of Acinetobacter species to various antimicrobial agents. Antimicrob. Agents Chemother. 30:769-770.
23. Seifert, H., R. Baginski, A. Schulze, and G. Pulverer. 1993. Antimicrobial susceptibility of Acinetobacter species. Antimicrob. Agents Chemother. 37: 750-753.
24. Shalit, I., M. Dan, R. Gutman, A. Gorea, and S. A. Berger. 1990. Cross-resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus. Antimicrob. Agents Chemother. 34:494-495.
25. Simor, A. E., L. Louie, and M. Louie. 1994. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/tazobactam and thirteen other antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 13:521-523.
26. Spangler, S. K., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfame-thoxazole, and imipenem. Antimicrob. Agents Chemother. 40:772-775.
27. Tanaka, M., M. Otsuki, T. Une, and T. Nishino. 1990. In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. J. Antimicrob. Chemother. 26:659-666.
28. Visser, M. R., M. Rozenberg-Arska, H. Beumer, I. M. Hoepelman, and J. Verhoef. 1991. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob. Agents Chemother. 35:858-868.
29. Von Graevenitz, A. 1995. Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative gram-negative bacteria, p. 520-532. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
30. Von Graevenitz, A., and C. Bucher. 1982. The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative gram-negative rods. Aeromonas, Plesiomonas and Enterobacter agglomerans. Infection 10:293-298.